Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16769
Title: NADPH oxidase-nox5 accelerates renal injury in diabetic nephropathy
Austin Authors: Jha, Jay C;Banal, Claudine;Okabe, Jun;Gray, Stephen P;Hettige, Thushan;Chow, Bryna SM;Thallas-Bonke, Vicki;De Vos, Lisanne;Holterman, Chet E;Coughlan, Melinda T;Power, David A ;Skene, Alison ;Ekinci, Elif I ;Cooper, Mark E;Touyz, Rhian M;Kennedy, Chris R;Jandeleit-Dahm, Karin
Affiliation: Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia
Institute of Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne
Department of Diabetes, Central Clinical School, Monash University, Australia
Human Epigenetics Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne
Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, Canada
Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia
Endocrine Centre, Austin Health, Repatriation Campus, Heidelberg, Victoria, Australia
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Issue Date: 26-Jul-2017
Publication information: Diabetes 2017; online first: 26 July
Abstract: NADPH-oxidase derived excessive production of reactive oxygen species (ROS) in the kidney plays a key role in mediating renal injury in diabetes. Pathological changes in diabetes include mesangial expansion and accumulation of extracellular matrix (ECM) leading to glomerulosclerosis. There is a paucity of data about the role of the Nox5 isoform of NADPH oxidase in animal models of diabetic nephropathy since Nox5 is absent in the mouse genome. Thus, we examined the role of Nox5 in human diabetic nephropathy, in human mesangial cells and in an inducible human Nox5 transgenic mouse exposed to STZ-induced diabetes.In human kidney biopsies, Nox5 was identified to be expressed in glomeruli which appeared to be increased in diabetes. Co-localisation demonstrated Nox5 expression in mesangial cells. In vitro, silencing of Nox5 in human mesangial cells was associated with attenuation of the hyperglycemia and TGF-β1 induced enhanced ROS production, increased expression of pro-fibrotic and pro-inflammatory mediators as well as increased TRPC6, PKC- α and PKC- β expression. In vivo, vascular smooth muscle cell (VSMC)/mesangial cell specific over expression of Nox5 in a mouse model of diabetic nephropathy showed enhanced glomerular ROS production, accelerated glomerulosclerosis, mesangial expansion and ECM protein (collagen IV and fibronectin) accumulation as well as increased macrophage infiltration and expression of the pro-inflammatory chemokine MCP-1. Collectively, this study provides evidence of a role for Nox5 and its derived ROS in promoting progression of diabetic nephropathy.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16769
DOI: 10.2337/db16-1585
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28747378
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Nov 25, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.